FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade

/PRNewswire/ -- Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved...

Related Keywords

Boston ,Massachusetts ,United States ,American ,America ,Marlena Abdinoor ,Dermatol Venereol ,Donna Atherton ,Sloan Simpson ,Hidradenitis Suppurativa ,Alexab Kimball ,Julie Masow ,A Hidradenitis Suppurativa ,Prnewswire Novartis ,Michael Meo ,Novartis Cosentyx ,Professor Of Dermatology At Harvard Medical School ,Novartis Europharm ,Exchange Commission ,American Academy Of Dermatology ,Novartis ,Drug Administration ,Novartis Pharmaceuticals Corp ,International Association Of Hidradenitis Suppurativa Network ,Novartis Pharmaceuticals Corporation ,Harvard Medical School ,Harvard Medical Faculty Physicians ,Beth Israel Deaconess Medical Center ,Chief Mission Officer ,International Association ,Hidradenitis Suppurativa Network ,Hidradenitis Suppurativa Clinical Response ,Victor Bult ,Medication Guide ,East Hanover ,Rev Dis ,Its Effect ,Clin Cosmet Investig ,Severe Hidradenitis Suppurativa ,American Academy ,New Orleans ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,